Maintaining Reduced Viral Fitness and CD4 Response in HIV‐Infected Patients with Viremia Receiving a Boosted Protease Inhibitor | Zendy

Philip Grant | Zendy; Jonathan Taylor | Zendy; Pat Cain | Zendy; William R. Short | Zendy; Joel E. Gallant | Zendy; Charles Farthing | Zendy; Gary Thal | Zendy; Eoin Coakley | Zendy; Andrew Zolopa | Zendy

Open Access

Maintaining Reduced Viral Fitness and CD4 Response in HIV‐Infected Patients with Viremia Receiving a Boosted Protease Inhibitor

Author(s) -

Philip Grant,

Jonathan Taylor,

Pat Cain,

William R. Short,

Joel E. Gallant,

Charles Farthing,

Gary Thal,

Eoin Coakley,

Andrew Zolopa

Publication year - 2009

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/597008

Subject(s) - atazanavir , viremia , medicine , protease inhibitor (pharmacology) , virology , protease , immunology , viral load , lentivirus , viral replication , virus , viral disease , antiretroviral therapy , biology , enzyme , biochemistry

When fully suppressive regimens are not available, incompletely suppressive regimens also provide immunologic benefits. In this study, with stable background therapy, human immunodeficiency virus (HIV)-infected patients who were randomized to receive atazanavir or boosted atazanavir, compared with those who continued boosted protease inhibitor therapy, maintained similar virologic and immunologic control, resistance-mutation patterns, and replication capacities with reduced use of lipid-lowering medication.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research